Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Incyte Corporation

http://www.incyte.com

Latest From Incyte Corporation

Abingworth Adds Stakes To Gilead’s Trodelvy Gamble

The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.

Commercial Clinical Trials

Ironwood Hits Phase III Endpoint In SBS-IF, But Shareholders Show Wariness

Looking to compete with Takeda’s Gattex in short bowel syndrome with intestinal failure, Ironwood succeeds in a Phase III trial, but investors may be concerned with misses on secondary endpoints.

Clinical Trials Drug Approval Standards

Remibrutinib REMIXes The Itch Record

Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.

Clinical Trials Companies

Incyte Enters A Data-Rich Year On Path To Portfolio Diversification

Incyte’s Jakafi-dominated portfolio gained Opzelura as a second source of significant revenue in 2021. While further diversification has been limited, new and existing R&D assets may deliver upside in 2024.

Strategy Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Other Names / Subsidiaries
    • Maxia Pharmaceuticals, Inc.
UsernamePublicRestriction

Register